Cargando…

APOE – a genetic marker of comorbidity in subjects with morbid obesity

BACKGROUND: In population-based studies, the genetic variability of the APOE E alleles have been associated with health outcomes. Health problems are common in subjects with obesity. This study explored associations between the APOE E alleles and comorbidity in subjects with morbid obesity. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Farup, Per G., Rootwelt, Helge, Hestad, Knut
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346600/
https://www.ncbi.nlm.nih.gov/pubmed/32646381
http://dx.doi.org/10.1186/s12881-020-01082-2
_version_ 1783556430310146048
author Farup, Per G.
Rootwelt, Helge
Hestad, Knut
author_facet Farup, Per G.
Rootwelt, Helge
Hestad, Knut
author_sort Farup, Per G.
collection PubMed
description BACKGROUND: In population-based studies, the genetic variability of the APOE E alleles have been associated with health outcomes. Health problems are common in subjects with obesity. This study explored associations between the APOE E alleles and comorbidity in subjects with morbid obesity. METHODS: The study included consecutive subjects referred for evaluation of bariatric surgery with morbid obesity (defined as BMI > 40 or > 35 kg/m(2) with complications related to obesity). The subjects followed a conservative weight loss program for 6 months before surgery and had a follow-up visit 12 months after surgery. Demographic data and a set psychosomatic scores (musculoskeletal pain, WHO-5 Well-Being Index, Rosenberg Self-Esteem Scale, Hopkins Symptom Check-list 10; Epworth Sleepiness Scale, and Fatigue Severity Scale) were collected, and blood samples were analysed for haematological and biochemical parameters and APOE alleles. RESULTS: One hundred and forty subjects (men/women: 32 (23%)/108 (77%) with mean age 43.0 (SD 8.7) years and BMI 42.1 (SD 3.8) kg/m(2) were included. One hundred and eight and 92 subjects had data after conservative treatment and 12 months after surgery, respectively. The prevalence of the APOE alleles were: E2E2: 1 (0.7%), E2E3: 13 (9.3%), E2E4: 4 (2.9%), E3E3: 71 (50.7%), E3E4: 47 (33.6%), and E4E4: 4 (2.9%). The prevalence rates were as anticipated in a Norwegian population. The weight loss during conservative treatment and after bariatric surgery was independent of E allele variability. E2 was associated with a significant or clear trend toward improvement of all psychosomatic disorders. There was a significant fall in CRP during the two treatment periods with weight loss. E2 and E4 were significantly associated with high and low CRP, respectively, but no associations were seen between CRP and comorbidity. CONCLUSIONS: The most marked finding was the association between E2 and improvement of all psychosomatic disorders. The positive and negative associations between CRP and E2 and E4, respectively, could indicate effects on inflammation and immunological reactions.
format Online
Article
Text
id pubmed-7346600
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-73466002020-07-14 APOE – a genetic marker of comorbidity in subjects with morbid obesity Farup, Per G. Rootwelt, Helge Hestad, Knut BMC Med Genet Research Article BACKGROUND: In population-based studies, the genetic variability of the APOE E alleles have been associated with health outcomes. Health problems are common in subjects with obesity. This study explored associations between the APOE E alleles and comorbidity in subjects with morbid obesity. METHODS: The study included consecutive subjects referred for evaluation of bariatric surgery with morbid obesity (defined as BMI > 40 or > 35 kg/m(2) with complications related to obesity). The subjects followed a conservative weight loss program for 6 months before surgery and had a follow-up visit 12 months after surgery. Demographic data and a set psychosomatic scores (musculoskeletal pain, WHO-5 Well-Being Index, Rosenberg Self-Esteem Scale, Hopkins Symptom Check-list 10; Epworth Sleepiness Scale, and Fatigue Severity Scale) were collected, and blood samples were analysed for haematological and biochemical parameters and APOE alleles. RESULTS: One hundred and forty subjects (men/women: 32 (23%)/108 (77%) with mean age 43.0 (SD 8.7) years and BMI 42.1 (SD 3.8) kg/m(2) were included. One hundred and eight and 92 subjects had data after conservative treatment and 12 months after surgery, respectively. The prevalence of the APOE alleles were: E2E2: 1 (0.7%), E2E3: 13 (9.3%), E2E4: 4 (2.9%), E3E3: 71 (50.7%), E3E4: 47 (33.6%), and E4E4: 4 (2.9%). The prevalence rates were as anticipated in a Norwegian population. The weight loss during conservative treatment and after bariatric surgery was independent of E allele variability. E2 was associated with a significant or clear trend toward improvement of all psychosomatic disorders. There was a significant fall in CRP during the two treatment periods with weight loss. E2 and E4 were significantly associated with high and low CRP, respectively, but no associations were seen between CRP and comorbidity. CONCLUSIONS: The most marked finding was the association between E2 and improvement of all psychosomatic disorders. The positive and negative associations between CRP and E2 and E4, respectively, could indicate effects on inflammation and immunological reactions. BioMed Central 2020-07-09 /pmc/articles/PMC7346600/ /pubmed/32646381 http://dx.doi.org/10.1186/s12881-020-01082-2 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Farup, Per G.
Rootwelt, Helge
Hestad, Knut
APOE – a genetic marker of comorbidity in subjects with morbid obesity
title APOE – a genetic marker of comorbidity in subjects with morbid obesity
title_full APOE – a genetic marker of comorbidity in subjects with morbid obesity
title_fullStr APOE – a genetic marker of comorbidity in subjects with morbid obesity
title_full_unstemmed APOE – a genetic marker of comorbidity in subjects with morbid obesity
title_short APOE – a genetic marker of comorbidity in subjects with morbid obesity
title_sort apoe – a genetic marker of comorbidity in subjects with morbid obesity
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346600/
https://www.ncbi.nlm.nih.gov/pubmed/32646381
http://dx.doi.org/10.1186/s12881-020-01082-2
work_keys_str_mv AT farupperg apoeageneticmarkerofcomorbidityinsubjectswithmorbidobesity
AT rootwelthelge apoeageneticmarkerofcomorbidityinsubjectswithmorbidobesity
AT hestadknut apoeageneticmarkerofcomorbidityinsubjectswithmorbidobesity